Global Tumor Markers Immunoassay Market Growth (Status and Outlook) 2022-2028

Global Tumor Markers Immunoassay Market Growth (Status and Outlook) 2022-2028

Product Code:233812

Published Date: Jan 04,2022

Pages: 123

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

As the global economy mends, the 2021 growth of Tumor Markers Immunoassay will have significant change from previous year. According to our (LP Information) latest study, the global Tumor Markers Immunoassay market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Tumor Markers Immunoassay market size will reach USD  million in 2028, growing at a CAGR of  % over the analysis period.

The United States Tumor Markers Immunoassay market is expected at value of US$  million in 2021 and grow at approximately  % CAGR during review period. China constitutes a  % market for the global Tumor Markers Immunoassay market, reaching US$  million by the year 2028. As for the Europe Tumor Markers Immunoassay landscape, Germany is projected to reach US$  million by 2028 trailing a CAGR of  % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at  % and  % respectively for the next 5-year period.

Global main Tumor Markers Immunoassay players cover Clarity Diagnostics, LLC, CTK Biotech, Inc, DIALAB GmbH, and Ortho Clinical Diagnostics, etc. In terms of revenue, the global largest two companies occupy a share nearly  % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Markers Immunoassay market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
    ProGRP
    PSA (complexed, free, total))
    SCC (squamous cell carcinoma antigen)
    Serum HER-2/neu
    Thyroglobulin
    CA 72-4
    Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
    Liver Cancer
    Breast Cancer
    Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
    Clarity Diagnostics, LLC
    CTK Biotech, Inc
    DIALAB GmbH
    Ortho Clinical Diagnostics
    Polymedco, Inc
    DIAsource ImmunoAssays SA
    DRG International, Inc
    Fujirebio US, Inc
    Bioscience (Tianjin) Diagnostic Technology Co., Ltd
    Boson Biotech Co., Ltd
    Qualigen, Inc
    Randox Laboratories, Ltd
    Roche Diagnostic Corporation
    Siemens Healthineers
    Syntron Bioresearch, Inc
    Teco Diagnostics
    Thermo Fisher Scientific, Inc
    Tosoh Bioscience, Inc
    Diametra
    DiaSorin S.p.A